Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 125

1.

Prognostication of prostate cancer based on TOP2A protein and gene assessment: TOP2A in prostate cancer.

de Resende MF, Vieira S, Chinen LT, Chiappelli F, da Fonseca FP, Guimarães GC, Soares FA, Neves I, Pagotty S, Pellionisz PA, Barkhordarian A, Brant X, Rocha RM.

J Transl Med. 2013 Feb 11;11:36. doi: 10.1186/1479-5876-11-36.

2.

Evaluation of the prognostic role of centromere 17 gain and HER2/topoisomerase II alpha gene status and protein expression in patients with breast cancer treated with anthracycline-containing adjuvant chemotherapy: pooled analysis of two Hellenic Cooperative Oncology Group (HeCOG) phase III trials.

Fountzilas G, Dafni U, Bobos M, Kotoula V, Batistatou A, Xanthakis I, Papadimitriou C, Kostopoulos I, Koletsa T, Tsolaki E, Televantou D, Timotheadou E, Koutras A, Klouvas G, Samantas E, Pisanidis N, Karanikiotis C, Sfakianaki I, Pavlidis N, Gogas H, Linardou H, Kalogeras KT, Pectasides D, Dimopoulos MA.

BMC Cancer. 2013 Mar 28;13:163. doi: 10.1186/1471-2407-13-163.

3.

Analysis of ERBB2 and TOP2A gene status using fluorescence in situ hybridization versus immunohistochemistry in localized breast cancer.

Bouchalová K, Trojanec R, Kolár Z, Cwiertka K, Cernáková I, Mihál V, Hajdúch M.

Neoplasma. 2006;53(5):393-401.

PMID:
17013533
4.

[Topoisomerase IIalpha and HER2/neu gene alterations and their correlation in pancreatic ductal adenocarcinomas].

Liang ZY, Wang WZ, Gao J, Wu SF, Zeng X, Liu TH.

Zhonghua Bing Li Xue Za Zhi. 2007 Feb;36(2):102-6. Chinese.

PMID:
17493384
6.

Tumor topoisomerase II alpha status and response to anthracycline-based neoadjuvant chemotherapy in breast cancer.

Nikolényi A, Sükösd F, Kaizer L, Csörgo E, Vörös A, Uhercsák G, Ormándi K, Lázár G, Thurzó L, Brodowicz T, Kahán Z.

Oncology. 2011;80(3-4):269-77. doi: 10.1159/000329038. Epub 2011 Jul 7.

PMID:
21734419
7.

Comparison of immunohistochemical and fluorescence in situ hybridization assessment for HER-2/neu status in Taiwanese breast cancer patients.

Kuo SJ, Wang BB, Chang CS, Chen TH, Yeh KT, Lee DJ, Yin PL, Chen M.

Taiwan J Obstet Gynecol. 2007 Jun;46(2):146-51.

8.

Low-level TOP2A amplification in prostate cancer is associated with HER2 duplication, androgen resistance, and decreased survival.

Murphy AJ, Hughes CA, Barrett C, Magee H, Loftus B, O'Leary JJ, Sheils O.

Cancer Res. 2007 Mar 15;67(6):2893-8.

9.

TOP2A copy number and TOP2A expression in uterine benign smooth muscle tumours and leiomyosarcoma.

Baiocchi G, Poliseli FL, De Brot L, Mantoan H, Schiavon BN, Faloppa CC, Vassallo J, Soares FA, Cunha IW.

J Clin Pathol. 2016 Oct;69(10):884-9. doi: 10.1136/jclinpath-2015-203561. Epub 2016 Mar 18.

PMID:
26994023
10.

Topoisomerase 2A gene amplification in breast cancer. Critical evaluation of different FISH probes.

Varga Z, Moelans CB, Zuerrer-Hardi U, Ramach C, Behnke S, Kristiansen G, Moch H.

Breast Cancer Res Treat. 2012 Jun;133(3):929-35. doi: 10.1007/s10549-011-1873-8. Epub 2011 Nov 15.

PMID:
22083232
11.

HER2 and TOP2A in high-risk early breast cancer patients treated with adjuvant epirubicin-based dose-dense sequential chemotherapy.

Fountzilas G, Valavanis C, Kotoula V, Eleftheraki AG, Kalogeras KT, Tzaida O, Batistatou A, Kronenwett R, Wirtz RM, Bobos M, Timotheadou E, Soupos N, Pentheroudakis G, Gogas H, Vlachodimitropoulos D, Polychronidou G, Aravantinos G, Koutras A, Christodoulou C, Pectasides D, Arapantoni P.

J Transl Med. 2012 Jan 12;10:10. doi: 10.1186/1479-5876-10-10.

12.

Assessment of Topoisomerase II α status in breast cancer by quantitative PCR, gene expression microarrays, immunohistochemistry, and fluorescence in situ hybridization.

Romero A, Martín M, Cheang MC, López García-Asenjo JA, Oliva B, He X, de la Hoya M, García Sáenz JÁ, Arroyo Fernández M, Díaz Rubio E, Perou CM, Caldés Llopis T.

Am J Pathol. 2011 Apr;178(4):1453-60. doi: 10.1016/j.ajpath.2010.12.042. Review.

13.

[Abnormality of TOP2A expression and its gene copy number variations in neuroblastic tumors].

Chen JM, Zhou CJ, Ma XL, Guan DD, Yang LY, Yue P, Gong LP.

Zhonghua Bing Li Xue Za Zhi. 2016 Nov 8;45(11):748-754. doi: 10.3760/cma.j.issn.0529-5807.2016.11.002. Chinese.

PMID:
27821228
14.

Topoisomerase-1 and -2A gene copy numbers are elevated in mismatch repair-proficient colorectal cancers.

Sønderstrup IM, Nygård SB, Poulsen TS, Linnemann D, Stenvang J, Nielsen HJ, Bartek J, Brünner N, Nørgaard P, Riis L.

Mol Oncol. 2015 Jun;9(6):1207-17. doi: 10.1016/j.molonc.2015.02.009. Epub 2015 Mar 4.

15.

[Correlation of TOP2A gene expression and survival of breast cancer patients].

Meng H, Li WC, Wang LX, Li WB, Zhang L, Fan QX, Wang RL, Lu TY.

Zhonghua Zhong Liu Za Zhi. 2011 May;33(5):363-6. Chinese.

PMID:
21875466
16.

Chromosome 17 centromere duplication and responsiveness to anthracycline-based neoadjuvant chemotherapy in breast cancer.

Tibau A, López-Vilaró L, Pérez-Olabarria M, Vázquez T, Pons C, Gich I, Alonso C, Ojeda B, Ramón y Cajal T, Lerma E, Barnadas A, Escuin D.

Neoplasia. 2014 Oct 23;16(10):861-7. doi: 10.1016/j.neo.2014.08.012. eCollection 2014 Oct.

17.

The ability of biomarkers to predict systemic progression in men with high-risk prostate cancer treated surgically is dependent on ERG status.

Karnes RJ, Cheville JC, Ida CM, Sebo TJ, Nair AA, Tang H, Munz JM, Kosari F, Vasmatzis G.

Cancer Res. 2010 Nov 15;70(22):8994-9002. doi: 10.1158/0008-5472.CAN-10-1358. Epub 2010 Nov 9.

18.

Clinical significance of topoisomerase 2A expression and gene change in operable invasive breast cancer.

Qiao JH, Jiao DC, Lu ZD, Yang S, Liu ZZ.

Tumour Biol. 2015 Sep;36(9):6833-8. doi: 10.1007/s13277-015-3390-6. Epub 2015 Apr 7.

PMID:
25846735
19.

Utilization of fluorescence in situ hybridization with cytokeratin discriminators in TOP2A assessment of chemotherapy-treated patients with breast cancer.

Pierceall WE, Sprott KM, Heikkinen T, Heikkila P, Alaparthi L, Aittomaki K, Al-Adhami M, Villegas-Bergazzi V, Meyer JL, Kutok JL, Bartkova J, Bartek J, Nevanlinna H, Weaver DT, Blomqvist C.

Hum Pathol. 2012 Sep;43(9):1363-75. doi: 10.1016/j.humpath.2011.08.018. Epub 2011 Dec 26.

PMID:
22204715
20.

RRM1, TUBB3, TOP2A, CYP19A1, CYP2D6: Difference between mRNA and protein expression in predicting prognosis of breast cancer patients.

Xu YC, Zhang FC, Li JJ, Dai JQ, Liu Q, Tang L, Ma Y, Xu Q, Lin XL, Fan HB, Wang HX.

Oncol Rep. 2015 Oct;34(4):1883-94. doi: 10.3892/or.2015.4183. Epub 2015 Aug 7.

PMID:
26252353

Supplemental Content

Support Center